Geovax Labs Inc Dossier
Qualitative Analysis
Business overview
GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company focused on developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers. The company's primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate targeting mpox and smallpox. GEO-MVA is being advanced under an expedited regulatory pathway in Europe, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address critical global orthopoxvirus vaccine supply constraints. GeoVax's flagship oncology program is Gedeptin, a novel patented gene-directed enzyme prodrug therapy (GDEPT) for solid tumors, which has completed a multicenter Phase 1/2 trial for advanced head and neck cancers. The company previously developed GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, but discontinued the program in late April 2026 following the termination of its BARDA contract.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing capital allocation and operational focus toward the GEO-MVA vaccine candidate for mpox and smallpox, leveraging an expedited regulatory pathway aligned with the European Medicines Agency (EMA).
Expected impact: Establishes GeoVax as a key domestic and international supplier of MVA-based orthopoxvirus vaccines, addressing global supply constraints.
Discontinuing active development of the GEO-CM04S1 COVID-19 vaccine candidate to concentrate resources on lead programs (GEO-MVA and Gedeptin). This decision followed the termination of the BARDA-funded Phase 2b clinical trial contract by BARDA for the government's convenience.
Expected impact: Reduces cash burn and focuses organizational efforts on programs with the clearest regulatory and commercial pathways.
Advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) for solid tumors, including planned combination strategies involving immune checkpoint inhibitors in head and neck cancer.
Expected impact: Validates the therapeutic efficacy of the GDEPT platform in oncology and opens up potential expansion into other solid tumor indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Oxford Biomedica serves as GeoVax's primary contract development and manufacturing organization (CDMO) partner, producing clinical-grade vaccine materials under GMP standards to support clinical trials.
Terms: Fee-for-service contract manufacturing terms.
Grants GeoVax exclusive worldwide rights to develop and commercialize Gedeptin, its lead immuno-oncology platform.
Terms: Includes milestone payments upon clinical/regulatory achievements, royalties on commercial sales, and patent maintenance cost reimbursements.